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Abstract
Background: Safe, effective and affordable drug combinations against falciparum malaria are
urgently needed for the poor populations in malaria endemic countries. Methylene blue (MB)
combined with chloroquine (CQ) has been considered as one promising new regimen.
Objectives: The primary objective of this study was to evaluate the safety of CQ-MB in African
children with uncomplicated falciparum malaria. Secondary objectives were to assess the efficacy
and the acceptance of CQ-MB in a rural population of West Africa.
Methods: In this hospital-based randomized controlled trial, 226 children (6–59 months) with
uncomplicated falciparum malaria were treated in Burkina Faso. The children were 4:1 randomized
to CQ-MB (n = 181; 25 mg/kg CQ and 12 mg/kg MB over three days) or CQ (n = 45; 25 mg/kg
over three days) respectively. The primary outcome was the incidence of severe haemolysis or
other serious adverse events (SAEs). Efficacy outcomes were defined according to the WHO 2003
classification system. Patients were hospitalized for four days and followed up until day 14.
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Results:  No differences in the incidence of SAEs and other adverse events were observed
between children treated with CQ-MB (including 24 cases of G6PD deficiency) compared to
children treated with CQ. There was no case of severe haemolysis and also no significant difference
in mean haemoglobin between study groups. Treatment failure rates were 53.7% (95% CI [37.4%;
69.3%]) in the CQ group compared to 44.0% (95% CI [36.3%; 51.9%]) in the CQ-MB group.
Conclusion: MB is safe for the treatment of uncomplicated falciparum malaria, even in G6PD
deficient African children. However, the efficacy of the CQ-MB combination has not been sufficient
at the MB dose used in this study. Future studies need to assess the efficacy of MB at higher doses
and in combination with appropriate partner drugs.
Introduction
Malaria is globally responsible for 1.5 – 2.7 million deaths
per year and remains a leading cause of mortality in chil-
dren less than five years of age, especially in African coun-
tries [38,5]. Only a few safe and effective antimalarial
drugs are presently affordable for the great majority of
sub-Saharan African (SSA) populations [4,40]. The
increasing resistance of Plasmodium falciparum to chloro-
quine and other well-known antimalarials like sul-
phadoxine/pyrimethamine demonstrates the urgency of
developing new drugs against malaria [36]. The combina-
tion of the drugs chloroquine (CQ) and methylene blue
(MB) appears to be a promising new regimen in regions
where CQ sensitivity prevails [32].
MB is a registered drug for the treatment of methaemoglo-
binemia and is also applied for cancer treatment, mainly
at i.v. dosages of 1–2 mg/kg [18]. MB was already success-
fully used over 100 years ago for the treatment of malaria,
even in children [14,9,11]. It was forgotten when other
drugs (e.g. chloroquine) were introduced to the market. In
recent years in vitro experiments have confirmed the high
antimalarial potency of MB [1]. MB specifically inhibits
the glutathione reductase of the malarial parasite and it
prevents the polymerization of haem into haemozoin
similar to 4-amino-quinoline antimalarials [31,32]. It
has, thus, the potential to reverse CQ resistance
[10,22,13].
There is some concern that the application of MB could be
followed by haemolysis in glucose-6-phosphate dehydro-
genase (G6PD) deficient individuals in malaria-endemic
regions. This is likely to be not clinically relevant in West
Africa where the milder form (class III) of G6PD defi-
ciency dominates [12]. Moreover, the safety of CQ-MB is
supported by the results of two studies in adult popula-
tions in 2003. The combination was well tolerated in
healthy G6PD sufficient adult males and females from
Germany and in healthy G6PD deficient adult males from
Burkina Faso [30,20].
The primary objective of the present trial was to study the
safety of CQ-MB in young West African children with
uncomplicated falciparum malaria. Secondary objectives
were to assess efficacy and acceptance of the combination.
Materials and methods
Study area and patients
The study was conducted in the district hospital of Nouna
in the province of Kossi in north-western Burkina Faso.
Nouna town has about 20,000 inhabitants of different
ethnic groups. Formal health services in the Kossi prov-
ince are restricted to the district hospital and to a small
number of village-based health centres. Therefore, access
to health services is limited, particularly during the rainy
season [26]. The area is highly endemic for P. falciparum
malaria [25]. Most malaria transmission and disease takes
place during or shortly after the rainy season, which lasts
from July-October. CQ is the first-line treatment for
uncomplicated malaria in Burkina Faso. Day 14 CQ clin-
ical failure rates in the villages surrounding Nouna town
were shown to be around 10% in recent years [27].
The study was explained to the population of Nouna town
during a series of community meetings prior to selection
of study children. In October and November 2003, con-
secutive children aged 6–59 months presenting with
uncomplicated falciparum malaria (axillary temperature
≥ 37.5°C and ≥ 2,000 P. falciparum asexual parasites per µl
blood) at the outpatient department of Nouna district
hospital and whose parents or caretaker had given
informed consent were enrolled in the study. Most study
children were from the town of Nouna, only a few chil-
dren were from villages close to Nouna. Children with
complicated or severe malaria (repeated vomiting, sei-
zures or other neurological impairment), anaemia (hae-
moglobin <8 g/dl or haematocrit <24%) or any other
apparent significant disease (e.g. pneumonia, meningitis,
hepatitis, severe diarrhoea, measles, severe malnutrition)
were excluded from the trial.
Study design and procedures
The study was designed as a sex-stratified (male:female,
4:1) parallel group randomized controlled trial (RCT). In
each sex stratum, children were block-randomized by
envelopes to receive either treatment with CQ or CQ-MBMalaria Journal 2005, 4:45 http://www.malariajournal.com/content/4/1/45
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by computer-generated, randomly permutated codes. The
randomization ratio of CQ-MB : CQ was 4:1. The unbal-
anced stratification and randomization scheme was justi-
fied by the need to achieve a high number of G6PD
deficient children treated with CQ-MB. The prevalence of
G6PD deficiency in boys under five years is 18%, while
the prevalence in girls is below 4% [7]. The study was
open label, with blinding only for the laboratory techni-
cians responsible for parasite determination in blood
smears.
All study children received a standard total dose of 25 mg/
kg of CQ syrup (10 mg/ml) over a period of three days
(first and second day: 10 mg/kg, third day: 5 mg/kg).
Chloroquine was taken from the quality-controlled essen-
tial drug stock of the Ministry of Health. The CQ-MB
group additionally received orally a 0.5% MB solution (4
mg/kg/day) for three days, divided into morning and
evening doses (produced by Mayrhofer Pharmazeutika /
Linz, Austria).
All study children were hospitalized for four days, and
study medications were given according to weight-based
tables by a study nurse, directly supervised by a study phy-
sician. Axillary temperatures were taken every six hours
during the time of hospitalization. At least once during
the time of hospitalization, the colour of the urine was
checked to assess MB compliance through visual observa-
tion. In case of vomiting within half an hour after the
study medication, the medication was repeated. All drugs
were allowed as concomitant treatments, except dapsone
and other sulfones, acetanilide and phenacetin, nalidixic
acid, niridazole, nitrofurantoins and sulphonamides
(themselves known to cause haemolysis in certain types of
inherited G6PD deficiency) [12]. All children having fever
≥ 38.5°C received standard doses of paracetamol (10 mg/
kg every six hours) until symptoms subsided.
Study participants were examined by the study physicians
twice daily until discharge from hospital and again after
14 days. Treatment failures were treated according to
national guidelines with standard doses of sulfadoxine-
pyrimethamine (currently still the second-line treatment
in Burkina Faso) or with quinine i.m. or i.v. if indicated.
Acceptance of MB was evaluated at day 14 by asking the
caretakers standardized questions about adverse effects.
At inclusion, every day in hospital and on day 14 a blood
sample was taken and malaria parasitaemia (thin and
thick blood smears) as well as haemoglobin (in case of
venous blood sampling) and haematocrit values were
measured. After Giemsa-staining, all blood smears were
examined by two experienced laboratory technicians
blinded to the group allocation. In case of disagreement,
a third laboratory technician examined the slides. Thick
and thin blood films were analysed for the species-specific
asexual parasite density per µl by counting against 200
white blood cells and multiplying by 50. Slides were
declared negative if no parasites were seen in 400 fields on
the thick film. Re-examination of a 10% random sample
of blood films at the laboratory of the Heidelberg School
of Tropical Medicine showed a 95% concordance of
malaria diagnoses. Furthermore, serum creatinine levels
were monitored with a spectrophotometer (Ultrospec
1000®) during the time of hospitalization.
The G6PD status was determined at inclusion using the
NADPH fluorescence test of Beutler and Mitchell [2] in
miniaturized form on paper (NFP-test) [6,7]. The G6PD
results were later validated by PCR. Sequences flanking
the putative mutations were amplified in two separate
nested PCR assays [17]. The alleles were distinguished by
restriction fragment length polymorphism. Finally,
genetic resistance to CQ in the P. falciparum isolates was
estimated by analysing the prevalence of the mutation
K76T in the Pfcrt gene product according to Djimde et al.
[8]. Both, G6PD PCR and CQ resistance marker diagnosis
were conducted at the Tropical Institute in Berlin
(Germany).
The primary study endpoint was safety, assessed by the
frequency and proportion of children with at least one
serious adverse event that could be possibly, probably or
definitely related to the drug. Secondary endpoints were
efficacy outcomes, judged by the incidence of early treat-
ment failures (ETF) on day four and late clinical failures
(LCF), clinical failure (CF = ETF+LCF) and late parasito-
logical failures (LPF) on day 14; fever clearance time, par-
asite clearance time, change in haematocrit after four days
compared to baseline, incidence of observed or self-
reported adverse events over the 14 days follow-up period
and monitoring of concomitant drug intake. In addition,
the impact of G6PD status based on the NFP-test and PCR
genotyping on safety parameters was investigated. An
adverse event was defined according to internationally
established principles for Good Clinical Practice (GCP).
Statistical methods
With a study population of 200 children, 160 were rand-
omized into the CQ-MB group and with high probability
(80%) at least 22 G6PD deficient children will be exposed
to MB. In order to reject the Null hypothesis of a high
haemolysis risk (>20%) on a significance level of 5% and
with a power of 90% if the true risk is small (<2%), 22
G6PD deficient children were to be included. A total of
225 patients was planned and a 10% drop-out rate was
assumed. The WHO definitions for ETF, LCF and LPF were
applied [39]. Study days were defined as 24 h intervals
after first drug intake. Losses to follow-up and drop-outs
due to other reasons were considered as ETF or LCF,Malaria Journal 2005, 4:45 http://www.malariajournal.com/content/4/1/45
Page 4 of 9
(page number not for citation purposes)
depending on the time of drop-out in an intention-to-
treat manner. All tests used apart from the primary analy-
sis have exploratory character. The (continuity adjusted)
Chi square test (Chi) was used to compare rates, the non-
parametric Wilcoxon-Mann-Whitney test (WMW) to com-
pare metric or ordinal data. If possible, estimates and the
corresponding 95% confidence interval are given. The sta-
tistical calculation was performed with SAS release 8.02
(SAS® Institute Inc, Cary, NC, USA).
Roughly 5% mortality over the first five years of child-
hood in malaria endemic areas of SSA is directly caused by
malaria [34]. This implies an annual malaria specific mor-
tality risk of 1%. From a public health-related risk benefit
calculation it follows that a risk for life-threatening
haemolysis above 10% is not acceptable for a first-line
antimalarial drug, because it could increase the overall
childhood mortality. Assuming a G6PD deficiency preva-
lence of at least 10% in the CRSN study area and the fact
that every child in the CRSN study area will be treated at
least once per year with a malaria drug which eliminates
malaria related mortality, but implies life-threatening
haemolysis in less than 10% of G6PD deficient children,
the annual population risk would be below 1% (0.1 ×
0.1).
Ethical aspects
The trial was conducted in accordance with local law, the
internationally established principles for Good Clinical
Practice, which had their origin in the Declaration of Hel-
sinki of the World Medical Association, and in accordance
with the "Note for Guidance on Clinical Investigation of
Medicinal Products in Children". Data collection and
analysis followed established quality principles. The pro-
tocol was approved by the Ethics Committee of the Medi-
cal Faculty of Heidelberg University and the local Ethics
Committee in Burkina Faso. The safety of the trial was also
monitored by a data safety monitoring board (DSMB).
After having received detailed information from the study
physician about all risks and benefits of the study through
translation of a detailed research consent form into the
local language, caretakers were asked for their written con-
sent. They were clearly informed that they could withdraw
from the study at any time and without disadvantage. A
standard blood transfusion service was available at the
hospital, and study physicians and emergency medica-
tions were available 24 hours per day. For the study par-
ticipants not only malaria treatment but all treatments
were free of charge. Furthermore, all children in the spec-
ified age group who were presented to the hospital during
the study period for other conditions besides malaria also
received free treatment.
Results
Study group characteristics
229 children with uncomplicated malaria were enrolled
(Figure 1). Three boys in group CQ-MB were excluded on
day one, one left for family reasons before application of
the first medication, two refused to take the first dose of
MB. The following analysis is based on the remaining 226
children. This is the full analysis set (FAS) for the inten-
tion to treat analysis, 45 receiving CQ and 181 CQ-MB. In
group CQ and CQ-MB respectively 41/45 and 166/181
children had taken the study drugs as per protocol (= PP,
Figure 1). There were no statistically significant differences
in sex ratio, age (pWMW = 0.801), weight (pWMW = 0.898),
creatinine, malaria parasitaemia and the prevalence of the
genetic resistance marker pfcrt K76T of the malaria para-
sites (pChi = 0.793) between the two groups (Table 1).
There was no difference in the haemoglobin (pWMW =
0.864) but in haematocrit (pWMW = 0.007) values between
the treatment groups at baseline (Table 1). G6PD status
was assessed in all 226 children. Overall, 30/226 children
(13.3%, 95% CI [9.1%, 18.4%]) were diagnosed as G6PD
deficient using the NFP test (six in the CQ group, 24 in the
CQ-MB group) (Table 1). There was good agreement
between the NFP test and the PCR results; these findings
are published separately [23].
Compliance with study drugs
The compliance is illustrated in Figure 1. In some cases,
particularly in the CQ-MB group, the drug administration
needed repeating after being initially rejected by the chil-
dren (1/45 CQ, 35/181 CQ-MB). Application of the bit-
ter-tasting 0.5% MB solution was more difficult in
children <2 years compared to older children (26/61 ver-
sus 9/120, pChi < 0.0001).
Safety of study drugs
There was no case of severe haemolysis within the group
of 24 G6PD deficient children who received MB (one-
sided exact 95% CI [0%, 11.73%]). Combining these
results with the pilot study in adult males [20], no haemo-
lysis was observed in 98 G6PD-deficient subjects under
CQ-MB. This updates the risk estimate to 3% (upper con-
fidence bound). One patient in the G6PD sufficient CQ-
MB group had a serious adverse event (SAE; prolonged
hospitalization) which was unrelated to the study medica-
tion. The haemoglobin of this 21 months old girl with an
initially high parasitaemia of 193,000/µl and haemor-
rhagic diarrhoea dropped within four days from 11.8 g/dl
to 6.6 g/dl. There was no need for blood transfusion. With
quinine and antibiotics she quickly recovered within five
days after admission to hospital. There was only one
febrile child with severe jaundice (group CQ-MB), later
diagnosed to have acute hepatitis A. There was also no
marked difference in the incidence of adverse events
between the two groups (Table 2). Only pruritus wasMalaria Journal 2005, 4:45 http://www.malariajournal.com/content/4/1/45
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observed with a higher incidence in the CQ group com-
pared to the CQ-MB group (8/45 versus 9/181; pChi =
0.017). Until the end of hospitalization there was no sig-
nificant increase of serum creatinine in the CQ-MB versus
the CQ group.
There were no differences between CQ and CQ-MB study
groups in haemoglobin and haematocrit values over time
in both the G6PD deficient and sufficient subgroups
(Table 3). The absolute median increase in haematocrit
from baseline until day 14 was 2% with no differences
between the overall study groups and between the G6PD
deficient subgroups.
Efficacy of study drugs
Among the fully compliant patients there were 22/41
(53.7%, 95% CI [37.4%; 69.3%]) treatment failures in
group CQ (15 ETF, 7 LCF) and 73/166 (44.0%, 95% CI
[36.3%; 51.9%]) in group CQ-MB (48 ETF, 25 LCF).
Comparing CQ and CQ-MB no significant differences
were found regarding CF (pChi = 0.348, OR = 0.68, 95% CI
[0.34; 1.35]), ETF (pChi = 0.444, OR = 0.71, 95% CI [0.34;
1.45]), LCF (pChi = 0.938, OR = 0.86, 95% CI [0.34; 2.16])
and LPF (pChi= 1.0, OR = 1.04, 95% CI [0.37; 2.95])
(Table 4).
The median fever clearance time in the fully compliant
patients for group CQ compared with CQ-MB was 8.0 and
8.8 hours respectively (pWMW = 0.725) and the median
Flow chart of study patients Figure 1
Flow chart of study patients.
Flow chart of study patients
Lost-to follow up: n=0/4
Protocol violation: n=2/4
Lost-to follow up: n=2/2
Vomiting: n=0/5
Exclusion (CQ/CQ-MB)
Family reason: n=0/1
Refused 1st treatment: n=0/2
Randomized
n=229
CQ+MB: n=184
FAS: n=181
G6PD deficient: n=24
day 1-4: n=174
PP on day 14: n=166 PP on day 14: n=41
day 1-4: n=43
CQ: n=45
FAS: n=45
G6PD deficient: n=6Malaria Journal 2005, 4:45 http://www.malariajournal.com/content/4/1/45
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parasite clearance time was 91.3 and 86.4 hours respec-
tively (pWMW = 0.140). The group comparisons are similar
using the intention-to-treat approach.
Acceptance of study drugs
The acceptance of the MB treatment was good, despite
some blue staining of clothes by the children's urine.
There was no response from 4/181 caretakers, 94/181
stated that they had no problem with the CQ-MB treat-
ment, while 83/181 mentioned minor difficulties con-
cerning the washing procedure of the stained clothes.
Discussion
MB has been used systematically against malaria in differ-
ent patient populations during the late 19th and the early
20th century, but the effects of this drug were poorly doc-
Table 1: Baseline characteristics by study group
Characteristic CQ (N = 45) CQ-MB (N = 181) Total (N = 226)
Sex
- male 36(80.0%) 145(80.1%) 181(80.1%)
- female 9(20.0%) 36(19.9%) 45(19.9%)
Age [months]
- Mean ± SD 30.0 ± 13.1 29.5 ± 14.9 29.6 ± 14.5
- Median 28.0 27.0 27.5
Weight [kg]
- Mean ± SD 10.5 ± 2.8 10.6 ± 2.8 10.6 ± 2.8
- Median 10.0 10.0 10.0
G6PD deficiency (NFP-test)
- No 39 (86.7%) 157 (86.7%) 196 (86.7%)
- Yes 6 (13.3%) 24 (13.3%) 30 (13.3%)
pfcrt gene
- wildtype 11 (24.4%) 40 (22.6%) 51 (23.0%)
- K76T mutant 34 (75.6%) 137 (77.4%) 171 (77.0%)
- Missing data 0 4 4
Haemoglobin [g/dl]
- Mean ± SD 10.3 ± 1.3 10.4 ± 1.4 10.4 ± 1.4
- Median 10.2 10.2 10.2
Haematocrit [%]
- Mean ± SD 27.9 ± 2.6 29.4 ± 3.3 29.1 ± 3.2
- Median 28.0 30.0 28.0
Creatinine [µmol/l]
- Mean ± SD 75.3 ± 15.2 77.2 ± 14.5 76.8 ± 14.6
- Median 74.4 76.4 75.3
P. falciparum parasites/µl log10 values
- Mean ± SD 4.28 ± 0.54 4.35 ± 0.54 4.33 ± 0.54
- Median 4.32 4.38 4.36
- Min, Max 3.40, 5.29 3.08, 5.71 3.08, 5.71
Table 2: Adverse events according to MedDRA SOC by study group
CQ (N = 45) CQ-MB (N = 181)
Gastrointestinal disorders 23 (38.3%) 93 (41.5%)
Respiratory disorders 16 (26.7%) 78 (34.8%)
Infections and infestations 10 (16.7%) 38 (17.0%)
Skin and subcutaneous tissue disorders 8 (13.3%) a 9 (4.0%) a
Others 3 (5.1%) 6 (2.7%)
a p = 0.017Malaria Journal 2005, 4:45 http://www.malariajournal.com/content/4/1/45
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umented in these old studies [14,11,32]. The present
report provides the first data on the safety and efficacy of
methylene blue in young children with falciparum
malaria in SSA. MB was chosen to be applied in combina-
tion with CQ for reasons of expected synergy and poten-
tial reversal of CQ resistance and because combination
therapy is the new paradigm in malaria therapy
[32,37,28]. Moreover, CQ has been the first-line treat-
ment for malaria in Burkina Faso at the time of the study.
G6PD deficiency was diagnosed through a phenotypic
method and this method was shown to have a good con-
cordance with results from genotyping [23]. During treat-
ment of 181 children, including 24 G6PD-deficient
children with uncomplicated falciparum malaria in
Burkina Faso, no drug related SAEs and, particularly, no
cases of severe haemolysis were observed. This does not
mean that SAEs can be excluded totally, but the likelihood
is certainly smaller than the risk of young SSA children
dying from malaria [34]. Moreover, no other adverse
events likely to be related to the study drugs were noted.
Thus, the findings from this study for the first time dem-
onstrate the safety of a methylene blue-based
combination in the treatment of malaria in young chil-
dren of SSA. These results support previous findings on
the safety of CQ-MB in G6PD sufficient adults in Europe
and G6PD deficient adults in Burkina Faso [30,20].
Although there were no safety problems with the oral
combination of CQ-MB, the administration of the bitter-
tasting MB solution was sometimes difficult, especially in
younger children. As a consequence, a paediatric formula-
tion for taste-masking of MB is currently under
development.
The findings from this study show that MB appears to be
safe at an oral dose of up to 4 mg/kg/day over three days
in SSA populations with dominating class III G6PD defi-
ciency, despite its being on the list of drugs reported to
potentially cause severe haemolysis in G6PD-deficient
populations [12]. However, this listing at least in part,
may have its origin in falsely attributing haemolysis
caused by the underlying infectious disease to the drug
used for treatment [3]. Nevertheless, as MB is a redox-
cycling oxidant and G6PD has an important role in the
elimination of reactive oxygen species in the erythrocyte,
the safety of MB may be influenced by the prevailing type
of G6PD deficiency [15]. Further studies are needed in
populations where G6PD deficiency class II occurs [12].
Table 3: Changes of laboratory values between baseline and study day 3 (haemoglobin, Hb), day 4 (haematocrit, HCT) and day 14 
(HCT) by study group and G6PD status.
CQ CQ-MB Group Comparison
Baseline – day 3/4: G6PD 
deficient children
Changes in Hb [g/dl] (N = 26) 0.4 ± 1.2 -0.7 ± 1.5 [-0.4; 2.5], pWMW = 0.126
Changes in HCT [%] (N = 30) 1.3 ± 4.1 -1.4 ± 3.9 [-0.9; 6.4], pWMW = 0.259
G6PD sufficient children
Changes in Hb [g/dl] (N = 176) -0.5 ± 1.3 -0.4 ± 1.6 [-0.6; 0.6], pWMW = 0.906
Changes in HCT [%] (N = 193) -1.2 ± 2.8 -1.1 ± 4.1 [-1.5; 1.3], pWMW = 0.871
Baseline – day 14: G6PD 
deficient children
Changes in HCT [%] (N = 30) 1.3 ± 3.3 1.4 ± 3.4 [-3.2; 3.0], pWMW = 0.979
G6PD sufficient children
Changes in HCT [%] (N = 187) 1.9 ± 3.8 1.2 ± 5.1 [-1.1; 2.5], pWMW = 0.698
Mean ± SD and 95% CI for the mean difference; no difference in change of Hb, HCT between G6PD deficient and sufficient children in the CQ-MB 
group for Hb (pWMW = 0.538), HCT (day 4, pWMW = 0.897) and HCT (day 14, pWMW = 0.933)
Table 4: Efficacy according to study group (per protocol analysis)
CQ (N = 41) CQ-MB (N = 163)
Clinical failure (CF) 22 (53.7%) 73 (44.0%)
Early treatment failure (ETF) 15 (36.6%) 48 (28.9%)
Late clinical failure (LCF) 7 (17.1%) 25 (15.1%)
Late parasitological failure (LPF) 5 (12.2%) 21 (12.9%)Malaria Journal 2005, 4:45 http://www.malariajournal.com/content/4/1/45
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The combination of dapsone and chloroproguanil (Lap-
dap) has recently been registered for malaria therapy in
SSA [19]. With regard to the potential of haemolysis
development in G6PD-deficient populations, MB belongs
to the same risk category as dapsone [12]. Thus, our find-
ings may also be reassuring regarding the safety of dap-
sone. Lapdap is currently undergoing phase IV studies in
different SSA populations.
Compared to CQ resistance data from the surrounding
villages, the observed rate of clinical failures during CQ
treatment was surprisingly high in the urban/semi-urban
population of this study (details will be published sepa-
rately) [27]. In most of Burkina Faso, the level of resist-
ance to CQ has remained remarkably stable during recent
years [29,35,24]. However, much higher CQ failure rates
were already documented from the capital town Ouaga-
dougou [33]. As a consequence, a policy change regarding
first-line treatment of uncomplicated malaria in Burkina
Faso was decided upon in early 2005 and it is planned to
use artemisinin-based combination therapy (ACT) start-
ing in 2006.
There were no differences in baseline characteristics
between the two study groups, with the exception of a
higher haematocrit in the group CQ-MB compared to the
CQ group, a finding likely to be explained by chance. The
clinical failure rate was higher in the CQ arm (54%) com-
pared to the CQ-MB arm (44%), but this difference was
not significant. This result could possibly be explained by
too low a dose of MB chosen in this study. Such an
assumption is supported by much higher MB doses
reported for treatment of malaria patients some 100 years
ago [12,14,21,16]. In one of these studies, a good safety
and efficacy of MB at oral doses of 20–50 mg/kg/day MB
over several days to weeks was demonstrated during treat-
ment of 40 young children with malaria in Brasil [11].
However, in these times treatment was usually uncon-
trolled, and efficacy outcomes in these old publications
often were poorly documented. As a consequence of the
lack of efficacy of the CQ-MB combination in this study,
a MB dose finding study has been conducted in 2004 in
the same study area. Findings confirm the efficacy of MB
at higher doses and will be published separately.
In the present investigation, methylene blue was again
well accepted by the study population [20]. Staining of
clothes was not considered as a major problem by moth-
ers. Only in a few cases, two to three traditional washes
were needed before stains were totally removed (Sanon,
unpublished data). This confirms results from a former
experimental study on the reversibility of MB stains in
local clothes and supports findings from an anthropolog-
ical study – on community perceptions of blue urine and
blue clothes – conducted during the rainy season of the
year 2003 in the rural Nouna study area (Sanon, unpub-
lished data).
In conclusion, MB has been shown to be safe for the treat-
ment of uncomplicated falciparum malaria in young West
African children with a high prevalence of G6PD defi-
ciency. However, the efficacy of the CQ-MB combination
has not been sufficient at the MB dose used in this study.
Future studies need to assess the efficacy of MB at higher
doses and in combination with appropriate partner drugs.
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